NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lunac Therapeutics

Lunac Therapeutics

Private
LeedsHealthcare & Life Scienceshttps://www.lunactherapeutics.com/

Last Round

VC Round

May 13, 2021

Total Funding Raised

$7.45M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Lunac Therapeutics is a drug discovery company developing next-generation oral anticoagulants to treat and prevent thrombotic events without the bleeding risk associated with current therapies.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

Factor XIIa inhibitorFXIIa inhibitoranticoagulant therapyblood thinnerthrombosissmall molecule drugsafer anticoagulantsdrug discoverypreclinical developmentfirst-in-class drugbiotechblood clot preventionanticoagulant without bleeding riskpharmaceutical licensinghemostasisuniversity spin-out

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lunac Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Lunac Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Lunac Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 13, 2021
GrantDec 12, 2019
Series ANov 14, 2019

Lunac Therapeutics Investors

Notable investors and investment history

Lunac Therapeutics investors
InvestorRounds
University of LeedsSeries A
Epidarex CapitalVC Round, Series A
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 81% MoM.

  • May 14, 2026

    Monthly visitors increased 47% MoM.

Lunac Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lunac Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lunac Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeeds
Employee Range2
Year Founded2018
Last FundingMay 13, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.